CCR5 and myeloid sarcoma: In the study of Kulakova et al. (6), CCR5*d was more frequently found in Russian MS patients with optimal response to IFN-beta and GA non-responders, while CCR5*w/w was enriched in IFN-beta non-responders and GA responders.